losartan has been researched along with up 269-6 in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (54.55) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caussade, F; Cazes, M; Cloarec, A; Curé, G; Goyard, J; Kirchner, M; Nicolaï, E; Teulon, JM; Versigny, A; Virone-Oddos, A | 1 |
| Goldberg, MR; Greenlee, WJ; Irvin, JD; Prendergast, K; Smith, RD; Timmermans, PB; Wexler, RR | 1 |
| Giridhar, R; Murumkar, P; Naik, P; Yadav, MR | 1 |
| Caussade, F; Cazes, M; Cloarec, A; Delchambre, C; Versigny, A; Virone-Oddos, A | 1 |
| Cazes, M; Cloarec, A; Provost, D; Versigny, A | 1 |
| Caussade, F; Cazes, M; Cloarec, A; Desangle, V; Provost, D; Virone-Oddos, A | 1 |
| Mutschler, E; Palm, D; Soldner, A; Spahn-Langguth, H | 1 |
| Jugdutt, BI; Menon, V; O'Brien, DW; Xu, Y | 1 |
| Jugdutt, BI; Kumar, D; Menon, V; Moudgil, R; Musat-Marcu, S; Xu, Y | 1 |
| Jugdutt, BI; Menon, V; Moudgil, R; Xu, Y | 1 |
| Jugdutt, BI; Menon, V; Xu, Y | 1 |
2 review(s) available for losartan and up 269-6
| Article | Year |
|---|---|
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Humans; Receptors, Angiotensin; Structure-Activity Relationship | 1996 |
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Losartan | 2010 |
1 trial(s) available for losartan and up 269-6
| Article | Year |
|---|---|
A radioreceptor assay for the analysis of AT1-receptor antagonists. Correlation with complementary LC data reveals a potential contribution of active metabolites.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Proteins; Chromatography, High Pressure Liquid; Double-Blind Method; Humans; Imidazoles; Losartan; Male; Placebos; Pyrimidines; Radioligand Assay; Rats; Rats, Wistar; Receptors, Angiotensin; Reference Values; Sensitivity and Specificity; Tetrazoles | 1998 |
8 other study(ies) available for losartan and up 269-6
| Article | Year |
|---|---|
Synthesis and SAR studies of novel triazolopyrimidine derivatives as potent, orally active angiotensin II receptor antagonists.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Azoles; Hypertension; Male; Models, Molecular; Pyrimidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tetrazoles | 1994 |
In vitro pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist.
Topics: Adrenal Medulla; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Binding, Competitive; Biphenyl Compounds; Dose-Response Relationship, Drug; Imidazoles; In Vitro Techniques; Losartan; Male; Muscle, Smooth, Vascular; Pyrimidines; Radioligand Assay; Rats; Tetrazoles | 1995 |
In vivo pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist.
Topics: Administration, Oral; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Decerebrate State; Dogs; Dose-Response Relationship, Drug; Heart Rate; Imidazoles; Injections, Intravenous; Losartan; Male; Pyrimidines; Rats; Rats, Sprague-Dawley; Species Specificity; Tetrazoles; Vasoconstrictor Agents | 1995 |
In vitro and in vivo effects of UP 269-6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Carotid Arteries; Carotid Artery Injuries; Catheterization; Cell Division; Imidazoles; In Vitro Techniques; Losartan; Muscle Proteins; Muscle, Smooth, Vascular; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Wistar; Stimulation, Chemical; Tetrazoles | 1997 |
Efficacy of pretreatment with the angiotensin II type 1 receptor blocker UP269-6 and losartan in the dog: effect on hemodynamics and ischemia-reperfusion.
Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Animals; Dogs; Dose-Response Relationship, Drug; Female; Hemodynamics; Losartan; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Pyrimidines; Random Allocation; Receptors, Angiotensin; Tetrazoles | 2000 |
Postischemic apoptosis and functional recovery after angiotensin II type 1 receptor blockade in isolated working rat hearts.
Topics: Angiotensin Receptor Antagonists; Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspases; In Vitro Techniques; Losartan; Male; Myocardial Reperfusion Injury; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Tetrazoles; Tumor Suppressor Protein p53; Ventricular Function, Left | 2001 |
Effect of chronic AT(1) receptor antagonism on postischemic functional recovery and AT(1)/AT(2) receptor proteins in isolated working rat hearts.
Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Animals; Heart; In Vitro Techniques; Losartan; Male; Myocardial Ischemia; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles | 2001 |
Cardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C-epsilon in acutely reperfused myocardial infarction in the dog. Effect of UP269-6 and losartan on AT1 and AT2-recep
Topics: Angiotensin Receptor Antagonists; Animals; Blood Volume; Calcium Channels; Cardiotonic Agents; Cyclic GMP; Dogs; Enzyme Activation; Female; Hemodynamics; Inositol 1,4,5-Trisphosphate Receptors; Isoenzymes; Losartan; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Protein Kinase C; Protein Kinase C-epsilon; Pyrimidines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Tetrazoles; Time Factors; Ventricular Function, Left | 2000 |